Overview

GVAX Plus Checkpoint Blockade in Neuroblastoma

Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This research clinical trial is studying the creation and administration of GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX) in combination with nivolumab and ipilimumab as a possible treatment for neuroblastoma. The names of the study drugs involved in this study are: - GVAX Vaccine, an immunotherapy developed from surgically removed tumor tissue - Nivolumab - Ipilimumab
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
Ipilimumab
Nivolumab
Vaccines